Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

Cited In for PubMed (Select 22057347)

1.

Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds.

Liu N, Huang H, Dou QP, Liu J.

Oncoscience. 2015 May 31;2(5):457-66. eCollection 2015. Review.

2.
3.

Deubiquitinating enzymes as oncotargets.

McClurg UL, Robson CN.

Oncotarget. 2015 Apr 30;6(12):9657-68.

4.

Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo.

Tang Y, Geng Y, Luo J, Shen W, Zhu W, Meng C, Li M, Zhou X, Zhang S, Cao J.

Sci Rep. 2015 Mar 30;5:9476. doi: 10.1038/srep09476.

5.

Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.

Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M.

Oncotarget. 2015 Feb 28;6(6):4159-70.

6.

Structural basis for the activation and inhibition of the UCH37 deubiquitylase.

VanderLinden RT, Hemmis CW, Schmitt B, Ndoja A, Whitby FG, Robinson H, Cohen RE, Yao T, Hill CP.

Mol Cell. 2015 Mar 5;57(5):901-11. doi: 10.1016/j.molcel.2015.01.016. Epub 2015 Feb 19.

PMID:
25702872
7.

In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma.

Sanchez-Diaz PC, Hsiao TH, Zou Y, Sugalski AJ, Heim-Hall J, Chen Y, Langevin AM, Hung JY.

Oncoscience. 2014 Sep 23;1(9):599-608. eCollection 2014.

8.

Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction.

Vaden JH, Bhattacharyya BJ, Chen PC, Watson JA, Marshall AG, Phillips SE, Wilson JA, King GD, Miller RJ, Wilson SM.

Mol Neurodegener. 2015 Jan 10;10(1):3. doi: 10.1186/1750-1326-10-3.

9.

Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.

Flaherty DP, Miller JR, Garshott DM, Hedrick M, Gosalia P, Li Y, Milewski M, Sugarman E, Vasile S, Salaniwal S, Su Y, Smith LH, Chung TD, Pinkerton AB, Aubé J, Callaghan MU, Golden JE, Fribley AM, Kaufman RJ.

ACS Med Chem Lett. 2014 Oct 29;5(12):1278-1283. eCollection 2014 Dec 11.

PMID:
25530830
10.

Disassembly of Lys11 and mixed linkage polyubiquitin conjugates provides insights into function of proteasomal deubiquitinases Rpn11 and Ubp6.

Mansour W, Nakasone MA, von Delbrück M, Yu Z, Krutauz D, Reis N, Kleifeld O, Sommer T, Fushman D, Glickman MH.

J Biol Chem. 2015 Feb 20;290(8):4688-704. doi: 10.1074/jbc.M114.568295. Epub 2014 Nov 11.

PMID:
25389291
11.

Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Sarhan D, D'Arcy P, Lundqvist A.

Int J Mol Sci. 2014 Oct 14;15(10):18557-73. doi: 10.3390/ijms151018557. Review.

12.

Inhibitory effect of b-AP15 on the 20S proteasome.

Huang L, Jung K, Chen CH.

Biomolecules. 2014 Oct 14;4(4):931-9. doi: 10.3390/biom4040931.

13.

Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.

Sun C, Roboti P, Puumalainen MR, Fryknäs M, Wang X, D'Arcy P, Hult M, High S, Linder S, Swanton E.

PLoS One. 2014 Oct 6;9(10):e108839. doi: 10.1371/journal.pone.0108839. eCollection 2014.

14.

An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes.

Ristic G, Tsou WL, Todi SV.

Front Mol Neurosci. 2014 Aug 19;7:72. doi: 10.3389/fnmol.2014.00072. eCollection 2014. Review.

15.

Cell death and deubiquitinases: perspectives in cancer.

Bhattacharya S, Ghosh MK.

Biomed Res Int. 2014;2014:435197. doi: 10.1155/2014/435197. Epub 2014 Jul 9.

17.

Extended ubiquitin species are protein-based DUB inhibitors.

Krutauz D, Reis N, Nakasone MA, Siman P, Zhang D, Kirkpatrick DS, Gygi SP, Brik A, Fushman D, Glickman MH.

Nat Chem Biol. 2014 Aug;10(8):664-70. doi: 10.1038/nchembio.1574. Epub 2014 Jul 6.

18.

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

Potu H, Peterson LF, Pal A, Verhaegen M, Cao J, Talpaz M, Donato NJ.

Oncotarget. 2014 Jul 30;5(14):5559-69.

19.

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.

Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, Jiang L, Zhao C, Dong X, Zhou P, Li S, Wang S, Shi X, Dou PQ, Wang X, Liu J.

Oncotarget. 2014 Jul 30;5(14):5453-71.

20.

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Liu N, Liu C, Li X, Liao S, Song W, Yang C, Zhao C, Huang H, Guan L, Zhang P, Liu S, Hua X, Chen X, Zhou P, Lan X, Yi S, Wang S, Wang X, Dou QP, Liu J.

Sci Rep. 2014 Jun 10;4:5240. doi: 10.1038/srep05240.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk